Universitätsmedizin Frankfurt

The pediatric oncology team at Universitätsmedizin Frankfurt is conducting studies aimed at increasing event‑free survival for children diagnosed with high‑risk neuroblastoma.

• High‑dose chemotherapy regimens
• Radiotherapy dose optimization
• Chemoimmunotherapy with dinutuximab beta
• Metastatic response assessment

The trials, part of an international SIOP‑Europe collaboration, evaluate intensive induction, tandem high‑dose chemotherapy, and tailored radiotherapy to improve long‑term outcomes for affected children.

Researchers are testing whether intravenous thrombolysis with alteplase or tenecteplase can safely and effectively treat acute ischemic stroke patients who have recently taken direct oral anticoagulants.

• Safety of IV thrombolysis with DOACs
• Functional outcome measured by modified Rankin Scale
• Comparison of alteplase versus tenecteplase
• Integration into emergency stroke pathways

This non‑commercial trial, run at Universitätsmedizin Frankfurt, seeks to provide evidence for optimal emergency care decisions in this high‑risk patient group.